碳酸镧在终末期肾脏病患者中的降磷效果及对血管钙化的影响

Abstract
Figure/Table
References (18)
Related Citation (1)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the phosphorus lowering effect of Lanthanum Carbonate in patients with end-stage renal disease and its effect on vascular calcification. Methods A total of 260 patients with end-stage renal disease admitted to Dingzhou People′s Hospital from January 2017 to January 2020 were selected as the research objects, and they were divided into the observation group (130 cases) and the control group (130 cases) by computer random drawing. Both groups were treated with hemodialysis, while patients in the observation group were treated with Lanthanum Carbonate, and patients in the control group were treated with Calcium Carbonate. Blood calcium, blood phosphorus,calcium phosphorus products and blood parathyroid hormone (PTH) levels were compared between the two groups at different time points (immediately after treatment, 2 weeks after treatment, 4 weeks after treatment, 8 weeks after treatment, and 12 weeks after treatment). The time when the blood phosphorus levels of the patients in the two groups returned to normal was recorded. The total incidence of adverse reactions in the two groups during medication was counted. Results After 2, 4, 8 and 12 weeks of treatment, serum calcium, blood phosphorus, calcium phosphorus products and blood PTH levels in the observation group were lower than those in the control group, serum calcium in the observation group after 4, 8 and 12 weeks of treatment were lower than those in the control group, and the differences were statistically significant (P＜0.05). The time of blood phosphorus levels in the observation group returning to normal was (30.59±5.61) d, which was shorter than (39.86±6.02) d in the control group, and the difference was statistically significant (P＜0.05). The total incidence of adverse reactions in the observation group (3.85%) was lower than that in the control group (13.07%), and the difference was statistically significant (P＜0.05). Conclusion Lanthanum Carbonate can significantly reduce the level of serum phosphorus in patients with end-stage renal disease, and has no significant effect on the level of serum calcium, which has high safety and is worthy of clinical use.

Key words： Lanthanum Carbonate End-stage renal disease Phosphorus lowering effect Vascular calcification

Received: 13 October 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I19/127

[1]	赵静芳.碳酸镧治疗终末期肾脏病患者高磷血症效果观察[J].临床医药文献电子杂志，2019，6（82）：166-167.
[2]	邓菲，冯静，李怡，等.碳酸镧对维持性血液透析患者高磷血症的疗效及安全性[J].实用药物与临床，2017，20（4）：398-401.
[3]	杨毕，童宗武，卢永新.碳酸镧对慢性肾脏病患者各系统影响的研究进展[J].临床内科杂志，2018，35（10）：719-720.
[4]	左巍.碳酸镧治疗终末期肾脏病患者高磷血症80 例分析[J].中国医师杂志，2016，18（5）：761-763.
[5]	宣建伟.治疗终末期肾脏病患者高磷血症的非含钙磷结合剂的选择[J].药品评价，2018，15（13）：5-7，17.
[6]	李军，陈文.碳酸镧与碳酸钙治疗维持性血液透析患者高磷血症的疗效比较[J].实用临床医药杂志，2017，21（23）：120-121.
[7]	蔡震川，李培贵，张万军，等.碳酸镧与醋酸钙治疗维持性透析患者高磷血症的对比研究[J].实用医院临床杂志，2018，15（3）：175-178.
[8]	李清丽，黄统生，朱明志.碳酸镧在慢性肾脏病维持性血液透析高磷血症患者中的应用效果[J].中国民康医学，2020，32（13）：47-49.
[9]	陈雷，姜秋岩.碳酸镧与醋酸钙在血液透析患者中降低血磷的疗效比较[J].临床肾脏病杂志，2020，20（2）：157-161.
[10]	黎晓磊，孔耀中，肖观清，等.碳酸镧联合西那卡塞、骨化三醇治疗继发性甲状旁腺机能亢进1 例[J].国际移植与血液净化杂志，2019，17（5）：30-31.
[11]	王淑荣.碳酸镧联合不同血液净化方式对慢性肾脏病矿物质及骨代谢异常患者的影响[J].世界最新医学信息文摘（连续型电子期刊），2019，19（A3）：46-47.
[12]	田园，陈文.骨化三醇联合碳酸镧对慢性肾脏病合并继发性甲状旁腺功能亢进透析患者的疗效观察[J].实用临床医药杂志，2017，21（23）：116-117.
[13]	尉芝苗，聂柳燕，周奇，等.碳酸镧治疗慢性肾脏病高磷血症的系统评价再评价[J].中国循证医学杂志，2016，16（12）：1394-1400.
[14]	张蓬杰，杜鹏，罗红梅，等.碳酸镧联合不同血液净化方式对慢性肾脏病-矿物质和骨代谢异常患者钙磷代谢的影响[J].临床肾脏病杂志，2016，16（9）：543-547.
[15]	周瑛，傅鹏.碳酸镧与醋酸钙联合血液灌流治疗血透患者高磷血症疗效比较[J].医药前沿，2018，8（13）：201-202.
[16]	向清，黄雪霞，曾剑锋，等.新型磷结合剂在慢性肾脏病中应用的进展[J].临床医药文献电子杂志，2019，6（41）：192，194.
[17]	陈孜瑾，陈晓农.新型非含钙磷结合剂在慢性肾脏病-矿物质和骨异常患者中的临床应用[J].临床肾脏病杂志，2018，18（9）：582-585.
[18]	潘健忠.碳酸镧治疗终末期肾脏病患者高磷血症的临床分析[J].吉林医学，2018，39（1）：129-130.